Literature DB >> 16777168

Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Krystyna Mozdzanowska1, Jingqi Feng, Mark Eid, Darya Zharikova, Walter Gerhard.   

Abstract

The role of serum components in enhancing virus neutralizing (VN) activity of influenza virus A/PR/8/34 hemagglutinin (HA)-specific MAbs in vitro was investigated. The degree of enhancement depended on the MAb's fine specificity and heavy chain isotype and on type of serum. Greatest enhancement (>100-fold) was seen with sera from immunodeficient mice that lacked serum immunoglobulin. At least two serum components were involved: C1q and a heat-resistant factor. C1q was mandatory for enhancement, and other components of the complement system were not required. C1q appeared to operate by improving MAb-mediated inhibition of virus attachment to host cells and was most effective with MAbs that inhibited virus attachment poorly on their own. The heat-resistant factor enhanced VN activity only in the presence of C1q and appeared to operate by enhancing VN activity at a post-attachment stage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777168     DOI: 10.1016/j.virol.2006.05.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

2.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Authors:  Jae-Min Song; Jaber Hossain; Dae-Goon Yoo; Aleksandr S Lipatov; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Robert J Hogan; Ruben O Donis; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2010-06-26       Impact factor: 3.616

3.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

4.  Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals.

Authors:  Mary Dawn T Co; John Cruz; Akira Takeda; Francis A Ennis; Masanori Terajima
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

5.  Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

Authors:  John H Beigel; Jocelyn Voell; Chiung-yu Huang; Peter D Burbelo; H Clifford Lane
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

6.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

7.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

8.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

Review 9.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

10.  Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Dae-Goon Yoo; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.